Complex Regional Pain Syndrome stem cell therapy — your questions answered (2026)

About stem cell therapy for Complex Regional Pain Syndrome

Complex regional pain syndrome (CRPS) is a chronic pain condition that may follow injury or surgery and can involve sensory, autonomic, motor and trophic changes in a limb. Management is individualised and commonly includes rehabilitation, pain treatment and psychological support, with specialist interventions in selected cases. Mesenchymal stromal cells (MSCs) and other cell approaches are experimental; proposed inflammatory or neural mechanisms have not established clinical benefit. The registry table on this page lists relevant studies and their current recruitment status.

The evidence for Complex Regional Pain Syndrome

Evidence for CRPS cell therapy is very limited and does not establish efficacy. Preliminary or unpublished results, small samples and subjective outcomes cannot support a predictable pain or functional benefit. CRPS symptoms and placebo responses can vary substantially, making adequately blinded controls and long follow-up essential. No pooled response rate is published here. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Private investigational CRPS cell procedures can involve separate charges for assessment, repeat administration, monitoring, travel, accommodation and complication care. Prices do not indicate regulatory approval or expected pain relief. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. Evidence-based multidisciplinary CRPS care must not be delayed.

Can stem cells help CRPS?

Cell therapy for Complex Regional Pain Syndrome may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Which stage responds?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

How is it delivered?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Complex Regional Pain Syndrome programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Complex Regional Pain Syndrome (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Complex Regional Pain Syndrome overview · Complex Regional Pain Syndrome cost →